|January 15, 2013|
|07:06 EDT||IRWD||Ironwood exploring opportunities to strengthen clinical profile of linaclotide|
“The past several months have been a remarkable period of time for us at Ironwood – particularly with the commercial launch of LINZESS in the U.S. and the approval of Constella in the E.U.,” said Peter Hecht, CEO of Ironwood. “In December, the joint Ironwood and Forest team stocked LINZESS in over 44,000 pharmacies across the U.S. and began educating over 85,000 physicians. Looking ahead, we will continue to focus on the LINZESS launch, while also exploring development opportunities to strengthen the clinical profile of linaclotide and broaden the product label in other indications and geographies. We will also continue to progress our other pipeline programs, including potential linaclotide-based combination products, IW-9179 for functional dyspepsia and IW-2143 for anxiety, among others. Through these activities, we continue to work towards our overarching goals of delivering differentiated medicines to patients and value to our shareholders.”
News For IRWD From The Last 14 Days
Check below for free stories on IRWD the last two weeks.
|May 22, 2013|
|06:47 EDT||IRWD||Ironwood likely to raise money again in early 2014, says Cantor|
Cantor believes Ironwood's 10.5M share offering provides the company with adequate cash for another three-to-four quarters of operations. However, Cantor thinks Ironwood will need to raise money again in early 2014 and reiterates a Sell rating on the stock with a $9 price target.
|May 21, 2013|
|18:30 EDT||IRWD||Ironwood 10.5M share Secondary priced at $13.00|
JPMorgan, BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering.
|May 20, 2013|
|16:05 EDT||IRWD||Ironwood files to sell 10.5M shares of common stock|
J.P. Morgan and BofA Merrill Lynch are acting as joint bookrunning managers and as representatives of the underwriters for the offering. Morgan Stanley is acting as bookrunning manager for the offering.
|07:11 EDT||IRWD||Ironwood Linzess may not be suitable for some patients, says Cantor|
After analyzing clinical data, Cantor believes that doctors will stop prescribing Ironwood's Linzess to patients who are not getting relief from constipation from the drug initially, while other patients will stop using the drug after two to three months. After attending two events connected with the launch of the drug, the firm thinks interest in it is disappointing, and it reiterates a Sell rating on the stock.
|May 17, 2013|
|10:36 EDT||IRWD||Leerink's major/specialty pharma analyst holds analyst/Industry conference call|
Subscribe for More Information
|May 15, 2013|
|11:37 EDT||IRWD||High option volume stocks: CONN IRWD JASO LYV CSC|